Our focus is creating new technology leading to therapeutic breakthroughs that are simple enough to be widely available. 

​

Our founder, Dr. Daniel Capon, is recognized for inventing key advances in biotechnology, among them Fc fusion proteins, CAR-T, and the technology for producing fully human antibodies. These breakthroughs have generated over $200 billion in cumulative global revenues for therapeutics and cellular therapies that have reached a broad patient population.

 

In addition to his research, Dr. Capon has served as a scientific expert in patent litigation. His contributions as an inventor have helped establish the factors used by the United States Patent and Trademark Office to determine whether a patent application contains a written description that is adequate to support broad patent claims.